CTLT - Catalent, Inc.

NYSE - NYSE Delayed Price. Currency in USD
53.09
+1.03 (+1.98%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close52.06
Open52.05
Bid0.00 x 800
Ask0.00 x 800
Day's Range51.90 - 53.10
52 Week Range29.23 - 58.38
Volume791,514
Avg. Volume663,362
Market Cap7.8B
Beta (3Y Monthly)1.68
PE Ratio (TTM)56.36
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    Catalent, Inc. Reports First Quarter Fiscal 2020 Results

    SOMERSET, N.J.-- -- Q1'20 revenue of $664.7 million increased 20% as-reported, or 22% in constant currency, from Q1'19. Adjusted its operating segments to better align internal business unit structure with the "Follow the Molecule" strategy and increase focus on biologics-related technologies, resulting in four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, ...

  • Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases Using Zydis ODT Technology
    Business Wire

    Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases Using Zydis ODT Technology

    Cycle Pharmaceuticals Ltd is pleased to announce that it has signed an agreement with Catalent, Inc. , to develop innovative formulations targeting rare disease patients.

  • Business Wire

    Catalent, Inc. Announces First Quarter Fiscal Year 2020 Earnings Conference Webcast

    Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2020 ended September 30, 2019, before the market open on Tuesday, November 5, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.

  • Business Wire

    Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2027

    Catalent, Inc. (“Catalent”) (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $500.0 million in aggregate principal amount of 5.00% senior unsecured notes due 2027 (the “Notes”) at par. The Operating Subsidiary intends to use the net proceeds from the Private Offering to (i) repay in full the outstanding borrowings under its U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses and (iii) provide cash on its balance sheet for general corporate purposes.

  • Business Wire

    Catalent Announces Launch of Private Offering of $500 Million of Senior Unsecured Notes Due 2027

    Catalent, Inc. (“Catalent”) (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $500 million in aggregate principal amount of senior unsecured notes due 2027 (the “Notes”) in a private offering (the “Private Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Operating Subsidiary intends to use the net proceeds from the Private Offering to (i) repay in full the outstanding borrowings under its U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses, and (iii) provide cash on its balance sheet for general corporate purposes.

  • Business Wire

    Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

    Bristol-Myers Squibb Company (BMY) and Catalent, Inc. (CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.

  • Business Wire

    Catalent, Inc. to Present at the Jefferies Healthcare Conference

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Jefferies Healthcare Conference at 3:00 p.m.

  • Business Wire

    Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

    Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells, Catalent is positioned to capitalize on strong industry tailwinds in the potentially $40 billion addressable market for gene therapies.

  • Business Wire

    Catalent, Inc. Reports Third Quarter Fiscal 2019 Results

    SOMERSET, N.J.-- -- Q3'19 revenue of $617.5 million decreased 2% as-reported, but increased 2% in constant currency, from Q3'18, while Q3'19 YTD revenue of $1,792.3 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services segments; ...

  • Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion
    PR Newswire

    Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion

    SOMERSET, N.J. and BALTIMORE, April 15, 2019 /PRNewswire/ -- Catalent, Inc. (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. "Paragon's unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth.

  • Business Wire

    Catalent to Acquire Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

    Catalent, Inc. (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies, today announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion. “Paragon’s unparalleled expertise in the rapidly growing market of gene therapy manufacturing will be a transformative addition to our business that we believe will accelerate our long-term growth.

  • Business Wire

    Catalent, Inc. Announces Third Quarter Fiscal Year 2019 Earnings Conference Webcast

    Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the third quarter of fiscal year 2019 ended March 31, 2019, before the market open on Tuesday, May 7, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.

  • Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience
    PR Newswire

    Biohaven Broadens Senior Leadership Team With Veteran Pharma Commercial Experience

    NEW HAVEN, Conn., April 3, 2019 /PRNewswire/ -- (BHVN) - Biohaven Pharmaceutical Holding Company Ltd. (BHVN), today announced the appointment of William "BJ" Jones as Chief Commercial Officer, Migraine and Common Diseases. Mr. Jones will have oversight of the commercial development of the company's calcitonin gene-related peptide (CGRP) receptor antagonist platform portfolio and glutamate portfolio in Alzheimer's Disease (AD), obsessive compulsive disorder (OCD), and generalized anxiety disorder (GAD).

  • Business Wire

    Catalent, Inc. to Present at the Barclays Global Healthcare Conference

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Barclays Global Healthcare Conference at 2:35 p.m.

  • Business Wire

    Catalent Names Alessandro Maselli President and Chief Operating Officer

    Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Senior Vice President, Global Operations Alessandro Maselli has been appointed President and Chief Operating Officer, a new position within Catalent. Maselli will continue to report to John Chiminski, Chair and CEO of Catalent.

  • Business Wire

    Catalent, Inc. Reports Second Quarter Fiscal 2019 Results

    SOMERSET, N.J.-- -- Q2'19 revenue of $623.0 million increased 3% as-reported, or 5% in constant currency, from the prior-year period. Q2'19 YTD revenue of $1,174.8 million increased 2% as-reported, or 4% in constant currency, from the prior-year period. Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery and Clinical Supply Services segments; Juniper acquisition ...

  • GlobeNewswire

    Investor Expectations to Drive Momentum within Cognizant Technology Solutions, Public Service Enterprise Group, Iron Mountain, Catalent, QuinStreet, and Entravision Communications — Discovering Underlying Factors of Influence

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire

    Catalent, Inc. Announces Second Quarter Fiscal Year 2019 Earnings Conference Webcast

    Catalent, Inc. (CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the second quarter of fiscal year 2019 ended December 31, 2018, before the market open on Tuesday, February 5, 2019. Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalent’s website at http://investor.catalent.com. A supplemental slide presentation will also be available in the “Investors” section of Catalent’s website prior to the start of the webcast.

  • Business Wire

    Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities

    Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.